Good Start Genetics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Good Start Genetics, Inc.
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
Marc Jones is taking on the dual role of chief operating officer and chief financial officer at UK point-of-care diagnostics firm Atlas Genetics.
Genetic information specialist Invitae is spreading into the reproductive health market with the proposed acquisition of two genetic testing companies that are focused on this area. The addition of Good Start Genetics and Combinatrix will enable Invitae to gain a foothold in the lucrative perinatal. Prenatal and neonatal testing markets. These deals bring the total number of acquisitions made by Invitae to three this year so far.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Laboratory Testing Services
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing